Goldman Sachs says this 'defensive bellwether' stock is a buy
Analyst Asad Haider assumed coverage of the pharma giant and upgraded it to buy from neutral.
Asad Haider
since
auto-detected in 26 stories
26 days ago
page 1 of 1
since
auto-detected in 26 stories
26 days ago
page 1 of 1